3. Secuencia del tratamiento
Primary Endpoint for Cohort B (sequential administration) and Cohort C:
•Objective response (OR) as determined by BICR based on RECIST v1.1.
Key Inclusion/Exclusion Cohort C:
•
Must be either refractory or relapsed while receiving anti-PD-1 or anti-PD-L1
monotherapy, meet discontinuation criteria due to PD
